

CURRICULUM VITAE

Patricia A. Thompson-Carino, Ph.D.
Associate Professor, Tenured
Cellular and Molecular Medicine
College of Medicine
1515 N. Campbell Ave.
PO Box 245024
Tucson, AZ 85724-5024
Phone: (520) 626-3138
Fax: (520) 626-9275

CHRONOLOGY OF EDUCATION

- 1986 B.S., Biology, Summa Cum Laude
Angelo State University, San Angelo, TX
- 1993 Ph.D., Immunology/Microbiology
University of Texas Health Science Center, San Antonio, TX
“Characterization of Disease Causing Acetylcholine Receptor Reactive B- and T-Lymphocytes in Experimental Autoimmune Myasthenia Gravis”
- 1993 – 1994 Postdoctoral Fellowship, Virology and Immunology
Southwest Research Foundation, San Antonio, TX
- 1994 – 1995 Postdoctoral Fellowship, Molecular Immunology
University of Texas Health Science Center, San Antonio, TX
- 1996 – 1998 Postdoctoral Fellowship, Molecular Epidemiology
National Center for Toxicology Research, Jefferson, AR

CHRONOLOGY OF EMPLOYMENT

- 08/1993 – 01/1994 Instructor of Cell Biology, Department of Life Sciences, University of Texas, San Antonio, TX
- 03/1998 – 06/1999 Molecular Biologist and Staff Scientist, Division of Molecular Epidemiology, National Center for Toxicological Research, Jefferson, AR
- 06/1998 – 06/1999 Adjunct Professor, Department of Surgical Oncology, University of Arkansas Medical School, Little Rock, AR
- 07/1999 – 09/2001 Assistant Professor, Department of Epidemiology, Division of Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, TX
- 10/2001 – 03/2009 Assistant Professor, Department of Pathology, College of Medicine, University of Arizona, Tucson, AZ
- 10/2001 – Present Member, The University of Arizona Cancer Center, Tucson, AZ
- 10/2003 – Present Adjunct Faculty, Department of Nutritional Sciences, College of Agriculture, University of Arizona, Tucson, AZ
- 10/2004 – Present Member, Cancer Biology Interdisciplinary Graduate Program, University of Arizona, Tucson, AZ
- 02/2009 – 10/2010 Assistant Professor (Non-tenure eligible), Division of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ
- 10/2010 – Present Associate Professor (Tenure eligible), Department of Cellular and Molecular Medicine, College of Medicine, University of Arizona, Tucson, AZ
- 11/2011 – Present Program Leader, Cancer Prevention and Control Program, The University of Arizona Cancer Center, Tucson, AZ

HONORS AND AWARDS

- 1982 – 1986 Carr Academic Scholarship to Angelo State University, San Angelo, TX
- 1982 – 1984 Carr ROTC Scholarship to Angelo State University, San Angelo, TX
- 1986 Head of the River Ranch Honors Scholarship in Biology, Angelo State

University, San Angelo TX
 1991 Most Accomplished Graduate Student
 2008 Arizona Cancer Center Sydney Salmon Junior Investigator Award

SERVICE/OUTREACH (for last five years)

Local/State Outreach

2002 – 2007 Board Member and Grant's Chair, Southern Arizona Affiliate of Susan G. Komen for the Cure
 2007 – Present Advisory Council, Southern Arizona Affiliate of Susan G. Komen for the Cure
 2009 – Present Lytmos Review Group for state-specific initiatives
 2011 – Present Board Member and Grant's Chair, Southern Arizona Affiliate of Susan G. Komen for the Cure
 2006-2011 Regular interviewer for the University of Arizona College of Medicine (~10-12 medical student applicants per year)

National/International Outreach

2006 – Present Member, Colon Family Registry, Candidate Gene Studies Working Group
 2004 – 2007 Member, Epidemiology Study Section for the California Breast Cancer Research Program
 2006 – Present NIH Epidemiology (EPIC) Study Section (participate as Ad Hoc Reviewer ~2 times per year as reviewer with special expertise in biomarker studies)
 2006 – Present Reviewer, Breast, Prostate, and Colon Cancer Congressionally Mandated Department of Defense Research Programs (1-2 per year)
 2006 – Present Reviewer, Susan G. Komen for the Cure National Research Grants Program (annually)
 2006 – Present Member, Consortia PIs for ELLA Binational Breast Cancer Research Study
 2007 – Present Ad Hoc Member, Epidemiology Study Section for the California Breast Cancer Research Program
 2007 – Present Review, Florida Cancer Grant Program (2-3 per year)
 2010 – Present Scientific Advisor, Gliogene and Glioma Case Control International Consortium
 2011 – 2016 Consultant, Molecular Pathology Training Grant, University of Texas MD Anderson Cancer Center
 2011 Scientific Advisor, Amgen use of RANK Ligand inhibitors in breast cancer prevention and treatment
 2011 Pennsylvania Interim Performance Review, Oak Ridge Program (1 application with site visit)
 2011 – 2012 Member, Organizing Committee, American Society of Prevention Oncology
 Oct 2012 Begin as permanent member EPIC Study Section

Peer Reviewer

Review approximately 2-3 manuscripts monthly for largely cancer-related journals, including:

Cancer Epidemiology, Biomarkers and Prevention (Associate Editor)
Journal of the National Cancer Institute
Cancer Research
Carcinogenesis
Gastroenterology
Clinical Cancer Research
BMC Genomics
Journal of Clinical Oncology
Molecular Carcinogenesis
American Journal of Medicine
Cancer Prevention Research

2010 – Present Editorial Board, *Cancer Epidemiology, Biomarkers and Prevention*
 2011 – Present Editorial Board, *Frontiers in Genetics*

Departmental Committees

2009 – 2010 Graduate Student Recruitment/Selection Committee
 2010 – Present Cellular and Molecular Medicine Curriculum Committee
 2011 – Present Cellular and Molecular Medicine Faculty Recruitment Committee
 2012 – Present Equipment Committee Chair
 2012 – Present Department Annual Faculty Performance Review Criteria

College/Cancer Center Committees

2005 – 2006 Member, College of Medicine Admissions Committee
 2006 – 2007 Subcommittee Chair and Member, College of Medicine Admissions Committee
 2009 – Present Member, Arizona Cancer Center Equipment Committee
 2009 – Present Alternate, Arizona Cancer Center Space Committee
 2009 – Present Member, Arizona Cancer Center Data Safety and Monitoring Committee
 2009 – Present Member, GI SPORE Internal Advisory Committee
 Sept 2010 Member, Cancer Biology Training Program Review Committee
 2011 – Present Member, Arizona Cancer Center Cancer Biology Graduate Program Curriculum Committee
 2010 – Present Member, Arizona Cancer Center Director's Committee
 2010 – Present Member, Intramural Review Committee for Arizona Cancer Center ACS Funding

University Committees

None

PUBLICATIONS/CREATIVE ACTIVITY (Published or Accepted)**Book chapters, review articles (invited, peer-reviewed), and monographs**

1. Krolick KA, **Thompson PA**, Zoda TE, Mohan S, Barohn RJ, Yeh T-M. (1994). Immunological factors that influence disease severity in experimental autoimmune myasthenia gravis. In Hohlfeld R (Ed.), *Immunology of Neuromuscular Disease (Immunology and Medicine)* (pp. 209–34). Boston: Kluwer Academic Publishers.
2. Krolick KA, Zoda TE, **Thompson PA**. Examination of characteristics that may distinguish disease-causing from benign AChR-reactive antibodies in experimental autoimmune myasthenia gravis. *Advances in Neuroimmunology*. 1994;4(4):475–93.
3. Ambrosone C, **Thompson P**. Molecular epidemiology of epithelial tumors. *Current Opinion in Oncology*. 1998;10(5):467–74.
4. **Thompson PA**, Ambrosone C. Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. *Journal of the National Cancer Institute Monographs*. 2000;(27):125–34.
5. Stratton MS, Stratton SP, Dionne SO, **Thompson P**, Jongewaard IN, Hakim I, Dilley T, Garland L, Ranger-Moore J, Alberts DS, Ahmann FM. (2004). Treatment of Carcinogenesis. In Bronchud MH, Foote MA, Giaccone G, Olopade O, Workman P (Eds.), *Principles of Molecular Oncology, 2nd Edition* (pp. 607–73). Totowa, NJ: Humana Press.
6. **Thompson PA**, Lopez AM, Stopeck A. (2005). Breast Cancer Prevention. In Alberts DS, Hess LM (Eds.), *Fundamentals of Cancer Prevention* (pp. 255–76). Berlin: Springer-Verlag.
7. **Thompson PA**, Jacobs ET, Lance P, Martínez ME. Bioavailable IGF-1: not the culprit in obesity-related cancers? *Cellscience Reviews*. 2007;3(3):54.
8. **Thompson PA**. Counterpoint: Genetic risk feedback for common disease time to test the waters. *Cancer Epidemiology, Biomarkers and Prevention*. 2007;16(9):1727–9.
9. **Thompson PA**, Stopeck A. (2008). Breast Cancer Prevention. In Alberts DS, Hess LM (Eds.), *Fundamentals of Cancer Prevention., 2nd Edition* (pp. 347–76). Berlin: Springer-Verlag.
10. Thomson CA, **Thompson PA**. Healthy Lifestyle and Cancer Prevention. *American College of Sports Medicine's Health & Fitness Journal*. 2008;12(3):18–26.
11. **Thompson PA**, Gerner EW. Current concepts in colorectal cancer prevention. *Expert Review of Gastroenterology and Hepatology*. 2009;3(4):369–82.
12. Thomson CA, **Thompson PA**. Dietary patterns, risk and prognosis of breast cancer. *Future Oncology*. 2009;5(8):1257–69.
13. Lance P, **Thompson PA**. Perspective: Chemoprevention of colorectal neoplasia: translating scientific promise into clinical practice. *Journal of Carcinogenesis*. 2011;10:11.
14. **Thompson P A**, Gerner EW. Of timing and surrogates: a way forward for cancer chemoprevention. *Clinical Cancer Research*. 2011;17(11):3509–11.

Refereed journal articles of original research, published or accepted in final form

*INDICATES WORK DONE AS A GRADUATE STUDENT

1. Infante AJ, ***Thompson PA**, Krolick KA, Wall KA. Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes. *The Journal of Immunology*. 1991;146(9):2977–82.
2. ***Thompson PA**, Krolick KA. Subsetting of acetylcholine receptor-reactive antibodies by preparative isoelectric focusing. *Preparative Biochemistry*. 1991;21(4):229–35.

3. ***Thompson PA**, Krolick KA. Acetylcholine receptor-reactive antibodies in experimental autoimmune myasthenia gravis differing in disease-causing potential: subsetting of serum antibodies by preparative isoelectric focusing. *Clinical Immunology and Immunopathology*. 1992;62(2):199–209.
4. Sądziene A, Rosa PA, ***Thompson PA**, Hogan DM, Barbour AG. Antibody-resistant mutants of *Borrelia burgdorferi*: in vitro selection and characterization. *The Journal of Experimental Medicine*. 1992;176(3):799–809.
5. Infante AJ, Levcovitz H, Gordon V, Wall KA, ***Thompson PA**, Krolick KA. Preferential use of a T cell receptor V beta gene by acetylcholine receptor reactive T cells from myasthenia gravis-susceptible mice. *The Journal of Immunology*. 1992;148(11):3385–90.
6. ***Thompson PA**, Barohn RA, Krolick KA. Repetitive nerve stimulation vs. twitch tension in rats with EAMG. *Muscle & Nerve*. 1992;15(1):94–100.
7. Sadziene A, ***Thompson PA**, Barbour AG: *In vitro* inhibition of *Borrelia burgdorferi* growth by antibodies. *The Journal of Infectious Diseases*. 1993;167(1):165–72.
8. Infante AJ, Faler J, Chang S, Currier P, ***Thompson P**, Krolick K, Zborowski K, Kraig E. T-cell receptor expression in murine myasthenia gravis. *Annals of the New York Academy of Sciences*. 1993;681:292–4.
9. Krolick KA, ***Thompson PA**, Zoda TE, Yeh TM. Influence of immunological fine-specificity on the induction of experimental myasthenia gravis. *Annals of the New York Academy of Sciences*. 1993;681:179–97.
10. ***Thompson PA**, McAtee R, Infante AJ, Currier P, Beninati W, Krolick KA. V beta-specific immunotoxin selectively kills acetylcholine receptor-reactive T lymphocytes from mice with experimental autoimmune myasthenia gravis. *International Immunology*. 1994;6(12):1807–15.
11. ***Thompson PA**, Edlund SA, Krolick KA. Identification of an idiotypic associated with antibodies responsible for neuromuscular dysfunction in rats with experimental autoimmune myasthenia gravis. *Clinical Immunology and Immunopathology*. 1995;75(1):57–67.
12. Sadziene A, ***Thompson PA**, Barbour AG. A flagella-less mutant of *Borrelia burgdorferi* as a live attenuated vaccine in the murine model of Lyme disease. *The Journal of Infectious Diseases*. 1996;173(5):1184–93.
13. Sadziene A, ***Thompson PA**, Barbour AG. Antibody responses of rats and humans to flagella-less cells and OspA protein of *Borrelia burgdorferi*. *Annals of the New York Academy of Sciences*. 1996;797:140–50.
14. **Thompson PA**, Kadlubar FF, Vena SM, Hill HL, McClure GH, McDaniel LP, Ambrosone CB. Exfoliated ductal epithelial cells in human breast milk: a source of target tissue DNA for molecular epidemiologic studies of breast cancer. *Cancer Epidemiology, Biomarkers and Prevention*. 1998;7(1):37–42.
15. Kadlubar FF, Anderson KE, Häussermann S, Lang NP, Barone GW, **Thompson PA**, MacLeod SL, Chou MW, Mikhailova M, Plastaras J, Marnett LJ, Nair J, Velic I, Bartsch H. Comparison of DNA adduct levels associated with oxidative stress in human pancreas. *Mutation Research*. 1998;405(2):125–33.
16. **Thompson PA**, Shields PG, Freudenheim JL, Stone A, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Kadlubar FF, Ambrosone CB. Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. *Cancer Research*. 1998;58(10):2107–10.

17. Linehan LA, Warren WD, **Thompson PA**, Grusby MJ, Berton MT. STAT6 is required for IL-4-induced germline Ig gene transcription and switch recombination. *Journal of Immunology*. 1998;161(1):302–10.
18. **Thompson PA**, Seyedi F, Lang NP, MacLeod SL, Wogan GN, Anderson KE, Tang YM, Coles B, Kadlubar FF. Comparison of DNA adduct levels associated with exogenous and endogenous exposures in human pancreas in relation to metabolic genotype. *Mutation Research*. 1999;424(1–2):263–74.
19. Ambrosone CB, Freudenheim JL, **Thompson PA**, Bowman E, Vena JE, Marshall JR, Graham S, Laughlin R, Nemoto T, Shields PG: Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer. *Cancer Research*. 1999;59(3):602–6.
20. Sweeney C, McClure GY, Fares MY, Stone A, Coles BF, **Thompson PA**, Korourian S, Hutchins LF, Kadlubar FF, Ambrosone CB. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. *Cancer Research*. 2000;60(20):5621–4.
21. Tang YM, Green BL, Chen GF, **Thompson PA**, Lang NP, Shinde A, Lin DX, Tan W, Lyn-Cook BD, Hammons GJ, Kadlubar FF. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. *Pharmacogenetics*. 2000;10(9):761–6.
22. Wiese FW, **Thompson PA**, Kadlubar FF. Carcinogen substrate specificity of human COX-1 and COX-2. *Carcinogenesis*. 2001;22:5–10.
23. Muskhelishvili L, **Thompson PA**, Kusewitt DF, Wang C, Kadlubar FF. In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. *Journal of Histochemistry & Cytochemistry*. 2001;49(2):229–36.
24. Ambrosone CB, Sweeney C, Coles BF, **Thompson PA**, McClure GY, Korourian S, Fares MY, Stone A, Kadlubar FF, Hutchins LF. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. *Cancer Research*. 2001;61(19):7130–5.
25. Wiese R, Belosludtsev Y, Powdrill T, **Thompson P**, Hogan M. Simultaneous multi-analyte ELISA performed on a microarray platform. *Clinical Chemistry*. 2001;47(8):1451–57.
26. **Thompson PA**, DeMarini DM, Kadlubar FF, McClure GY, Brooks LR, Green BL, Fares MY, Stone A, Joseph PD, Ambrosone CB. Evidence for the presence of mutagenic arylamines in human breast milk and DNA adducts in exfoliated breast ductal epithelial cells. *Environmental and Molecular Mutagenesis*. 2002;39(2–3):134–42.
27. Lin DX, **Thompson PA**, Teitel C, Chen JS, Kadlubar FF. Direct reduction of N-acetoxy-PhIP by tea polyphenols: a possible mechanism for chemoprevention against PhIP-DNA adduct formation. *Mutation Research*. 2003;523–524:193–200.
28. Kuerer HM, **Thompson PA**, Krishnamurthy S, Fritsche HA, Marcy SM, Babiera GV, Singletary SE, Cristofanilli M, Sneige N, Hunt KK. High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer. *Clinical Cancer Research*. 2003;9(2):601–5.
29. Egan KM, **Thompson PA**, Titus-Ernstoff L, Moore JH, Ambrosone CB. MnSOD polymorphism and breast cancer in a population-based case-control study. *Cancer Letters*. 2003;199(1):27–33.
30. Krishnamurthy S, Sneige N, **Thompson PA**, Marcy SM, Singletary SE, Cristofanilli M, Hunt KK, Kuerer HM. Nipple aspirate fluid cytology in breast carcinoma. *Cancer*. 2003;99(2):97–104.

31. Wiese FW, **Thompson PA**, Warneke J, Einspahr J, Alberts DS, Kadlubar FF. Variation in cyclooxygenase expression levels within the colorectum. *Molecular Carcinogenesis*. 2003;37(1):25–31.
32. Martínez ME, **Thompson P**, Jacobs ET, Giovannucci E, Jiang R, Klimecki W, Alberts DS. Dietary factors and biomarkers involved in the methylenetetrahydrofolate reductase genotype-colorectal adenoma pathway. *Gastroenterology*. 2006;131(6):1706–16.
33. Jacobs ET, Lanza E, Alberts DS, Hsu CH, Jiang R, Schatzkin A, **Thompson PA**, Martínez ME. Fiber, sex, and colorectal adenoma: results of a pooled analysis. *The American Journal of Clinical Nutrition*. 2006;83(2):343–9.
34. Martínez ME, Giovannucci E, Jiang R, Henning SM, Jacobs ET, **Thompson P**, Smith-Warner SA, Alberts DS. Folate fortification, plasma folate, homocysteine and colorectal adenoma recurrence. *International Journal of Cancer*. 2006;119(6):1440–6.
35. Jacobs ET, Martínez ME, Alberts DS, Jiang R, Lance P, Lowe KA, **Thompson PA**. Association between body size and colorectal adenoma recurrence. *Clinical Gastroenterology and Hepatology*. 2007;5(8):982–90.
36. Martínez ME, Nielson CM, Nagle R, Lopez AM, Kim C, **Thompson, P**. Breast cancer among Hispanic and non-Hispanic White women in Arizona. *Journal of Health Care for the Poor and Underserved*. 2007;18(4 Suppl):130–45.
37. Jacobs ET, **Thompson PA**, Martínez ME. Diet, gender, and colorectal neoplasia. *Journal of Clinical Gastroenterology*. 2007;41(8):731–46.
38. Martínez ME, Jacobs ET, Ashbeck EL, Sinha R, Lance P, Alberts DS, **Thompson PA**. Meat intake, preparation methods, mutagens and colorectal adenoma recurrence. *Carcinogenesis*. 2007;28(9):2019–27.
39. Brewster AM, Do KA, **Thompson PA**, Hahn KM, Sahin AA, Cao Y, Stewart MM, Murray JL, Hortobagyi GN, Bondy ML. Relationship between epidemiologic risk factors and breast cancer recurrence. *Journal of Clinical Oncology*. 2007;25(28):4438–44.
40. Jacobs ET, Alberts DS, Benuzillo J, Hollis BW, **Thompson PA**, Martínez ME. Serum 25(OH)D levels, dietary intake of vitamin D, and colorectal adenoma recurrence. *The Journal of Steroid Biochemistry and Molecular Biology*. 2007;103(3–5):752–6.
41. Miller JA, Hakim IA, Thomson C, **Thompson P**, Chow HH. Determination of d-limonene in adipose tissue by gas chromatography-mass spectrometry. *Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences*. 2008;870(1):68–73.
42. Scheurer ME, El-Zein R, **Thompson PA**, Aldape KD, Levin VA, Gilbert MR, Weinberg JS, Bondy ML. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. *Cancer Epidemiology, Biomarkers and Prevention*. 2008;17(5):1277–81.
43. Jacobs ET, Martínez ME, Alberts DS, Ashbeck EL, Gapstur SM, Lance P, **Thompson PA**. Plasma insulin-like growth factor I is inversely associated with colorectal adenoma recurrence: A novel hypothesis. *Cancer Epidemiology, Biomarkers and Prevention*. 2008;17(2):300–5.
44. Egan JB, Jacobs ET, Martínez ME, Gerner EW, Jurutka PW, **Thompson PA**. Presence of a TA haplotype in the APC gene containing the common 1822 polymorphism and colorectal adenoma. *Cancer Research*. 2008;68(14):6006–13.
45. Wang Y, Carlton VE, Karlin-Neumann G, Sapolsky R, Zhang L, Moorhead M, Wang ZC, Richardson AL, Warren R, Walther A, Bondy M, Sahin A, Krahe R, Tuna M, **Thompson PA**, Spellman PT, Gray JW, Mills GB, Faham M. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. *BMC Medical Genomics*. 2009;2:8.

46. Jacobs ET, Ahnen DJ, Ashbeck EL, Baron JA, Greenberg ER, Lance P, Lieberman DA, McKeown-Eyssen G, Schatzkin A, **Thompson PA**, Martínez ME. Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling study. *American Journal of Epidemiology*. 2009;169(6):657–66.
47. Ashbeck EL, Jacobs ET, Martínez ME, Gerner EW, Lance P, **Thompson PA**. Components of metabolic syndrome and metachronous colorectal neoplasia. *Cancer Epidemiology, Biomarkers and Prevention*. 2009;18(4):1134–43.
48. Wertheim BC, Martínez ME, Ashbeck EL, Roe DJ, Jacobs ET, Alberts DS, **Thompson PA**. Physical activity as a determinant of fecal bile acid levels. *Cancer Epidemiology, Biomarkers and Prevention*. 2009;18(5):1591–8.
49. Flowers M, **Thompson PA**. t10c12 conjugated linoleic acid suppresses HER2 protein and enhances apoptosis in SKBr3 breast cancer cells: possible role of COX2. *Public Library of Science One*. 2009;4(4):e5342.
50. Thomson CA, **Thompson PA**, Bea JW, Nardi E, Frey GR, Stopeck AT. Metabolic syndrome and elevated C-reactive protein in breast cancer survivors on adjuvant hormone therapy. *Journal of Women's Health*. 2009;18(12):2041–7.
51. **Thompson PA**, Wertheim BC, Roe DJ, Ashbeck EL, Jacobs ET, Lance P, Martínez ME, Alberts DS. Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. *Cancer Prevention Research*. 2009;2(12):1023–30.
52. Bea JW, Lohman TG, Cussler EC, Going SB, **Thompson PA**. Lifestyle modifies the relationship between body composition and adrenergic receptor genetic polymorphisms ADRB2, ADRB3 and ADRA2B: a secondary analysis of a randomized controlled trial of physical activity among postmenopausal women. *Behavior Genetics*. 2010;40(5):649–59.
53. Martínez ME, Gutierrez-Millan LE, Bondy M, *et al.*, **Thompson PA**. Comparative study of breast cancer in Mexican and Mexican-American Women. *Health*. 2010;2(9):1040–8.
54. Martínez ME, Cruz GI, Brewster AM, Bondy ML, **Thompson PA**. What can we learn about disease etiology from case-case analyses? Lessons from breast cancer. *Cancer Epidemiology, Biomarkers and Prevention*. 2010;19:2710–4.
55. Bartley AN, **Thompson PA**, Buckmeier JA, Kepler CY, Hsu CH, Snyder MS, Lance P, Bhattacharyya A, Hamilton SR. Expression of gastric pyloric mucin, MUC6, in colorectal serrated polyps. *Modern Pathology*. 2010;23(2):169–76.
56. **Thompson PA**, Hsu CH, Green S, Stopeck AT, Johnson K, Alberts DS, Chow HH. Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial. *Cancer Prevention Research*. 2010;3(1):101–7.
57. Egan JB, **Thompson PA**, Ashbeck EL, Conti DV, Duggan D, Hibler E, Jurutka PW, Leroy EC, Martínez ME, Mount D, Jacobs ET. Genetic polymorphisms in vitamin D receptor VDR/RXRA influence likelihood of colon adenoma recurrence. *Cancer Research*. 2010;70(4):1496–504.
58. Egan JB, **Thompson PA**, Vitanov MV, Bartik L, Jacobs ET, Haussler MR, Gerner EW, Jurutka PW. Vitamin D receptor ligands, adenomatous polyposis coli, and the vitamin D receptor FokI polymorphism collectively modulate β -catenin activity in colon cancer cells. *Molecular Carcinogenesis*. 2010;49(4):337–52.
59. Algotar AM, **Thompson PA**, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP. Effect of aspirin, other NSAIDs, and statins on PSA and PSA velocity. *The Prostate*. 2010;70(8):883–8.
60. Hibler EA, Jurutka PW, Egan JB, Hu C, Leroy EC, Martínez ME, **Thompson PA**, Jacobs ET. Association between polymorphic variation in VDR and RXRA and circulating levels of

- vitamin D metabolites. *Journal of Steroid Biochemistry and Molecular Biology*. 2010;121(1–2):438–41.
61. **Thompson PA**, Wertheim BC, Zell JA, Pin Chen W, McLaren CE, Lafleur BJ, Meyskens FL, Gerner EW. Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of difluoromethylornithine and sulindac to prevent colorectal adenoma. *Gastroenterology*. 2010;139(3):797–805.
 62. Flowers M, Schroeder JA, Borowsky AD, Besselsen DG, Thomson CA, Pandey R, **Thompson PA**. Pilot study on the effects of dietary conjugated linoleic acid on tumorigenesis and gene expression in PyMT transgenic mice. *Carcinogenesis*. 2010;31(9):1642–9.
 63. Stratton MS, Algotar AM, Ranger-Moore J, Stratton SP, Slate EH, Hsu CH, **Thompson PA**, Clark LC, Ahmann FR. Oral selenium supplementation has no effect on prostate-specific antigen velocity in men undergoing active surveillance for localized prostate cancer. *Cancer Prevention Research*. 2010;3(8):1035–43.
 64. Miller JA, Hakim IA, Chew W, **Thompson P**, Thomson CA, Chow HH. Adipose tissue accumulation of d-limonene with the consumption of a lemonade preparation rich in d-limonene content. *Nutrition and Cancer*. 2010;62(6):783–8.
 65. Komenaka IK, Martínez ME, Pennington RE Jr, Hsu CH, Clare SE, **Thompson PA**, Murphy C, Zork NM, Goulet RJ Jr. Race and ethnicity and breast cancer outcomes in an underinsured population. *Journal of the National Cancer Institute*. 2010;102(15):1178–87.
 66. Jacobs ET, Martínez ME, Campbell PT, Conti DV, Duggan D, Figueiredo JC, Haile RW, Leroy EC, Poynter JN, **Thompson PA**, Baron JA. Genetic variation in the retinoid X receptor and calcium-sensing receptor and risk of colorectal cancer in the Colon Cancer Family Registry. *Carcinogenesis*. 2010;31(8):1412–6.
 67. Stendell-Hollis NR, Thomson CA, **Thompson PA**, Bea JW, Cussler EC, Hakim IA. Green tea improves metabolic biomarkers, not weight or body composition: a pilot study in overweight breast cancer survivors. *Journal of Human Nutrition and Dietetics*. 2010;23(6):590–600.
 68. Thomson CA, Rock CL, **Thompson PA**, Caan BJ, Cussler E, Flatt SW, Pierce JP. Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the Women's Healthy Eating and Living Study. *Breast Cancer Research and Treatment*. 2011;125(2):519–27.
 69. Zell JA, McLaren CE, Chen W-P, **Thompson PA**, Gerner EW, Meyskens FL. Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients. *Journal of the National Cancer Institute*. 2010; 102(19):1513–6.
 70. Miranda PY, Wilkinson AV, Etzel CJ, Zhou R, Jones LA, **Thompson PA**, Bondy ML. Policy Implications of early onset breast cancer among Mexican-origin women. *Cancer*. 2011;117(2):390–7.
 71. Abalos AT, Eggers R, Hogan M, Nielson CM, Giuliano AR, Harris RB, **Thompson PA**. Design and validation of a multiplex specific primer-directed polymerase chain reaction assay for killer-cell immunoglobulin-like receptor genetic profiling. *Tissue Antigens*. 2011;77(2):143–8.
 72. Algotar AM, Stratton SP, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, **Thompson PA**. Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer. *American Journal of Men's Health*. 2011;5(3):272–8.

73. Bea JW, Wright NC, **Thompson P**, Hu C, Guerra S, Chen Z. Performance evaluation of a multiplex assay for future use in biomarker discovery efforts to predict body composition. *Clinical Chemistry and Laboratory Medicine*. 2011;49(5):817–24.
74. LeRoy EC, Moore JH, Hu C, Martínez ME, Lance P, Duggan D, **Thompson PA**. Genes in the insulin and insulin-like growth factor pathway and odds of metachronous colorectal neoplasia. *Human Genetics*. 2011;129(5):503–12.
75. Stendell-Hollis NR, Lauder milk MJ, West JL, **Thompson PA**, Thomson CA. Recruitment of lactating women into a randomized dietary intervention: successful strategies and factors promoting enrollment and retention. *Contemporary Clinical Trials*. 2011;32(4):505–11.
76. Nodora J, Martz W, Ashbeck E, Jacobs E, **Thompson P**, Martínez M. Primary care physician compliance with colorectal cancer screening guidelines. *Cancer Causes and Control*. 2011;22(9):1277–87.
77. Brewster AM, **Thompson, PA**, Sahin AA, Do K, Edgerton M. Murray JL, Tsavachidis S, Zhou R, Liu Y, Zhang L Mills G, Bondy M. Copy number imbalances between screen and symptom-detected breast cancers and impact on disease-free survival. *Cancer Prevention Research*. 2011;4(10):1609–16.
78. **Thompson PA**, Brewster AM, Broom BM, Do K, Edgerton ME, Hahn KM, Murray JL, Sahin AA, Tsavachidis S, Zhang L, Hortobagyi GN, Mills GB, Bondy ML. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. *Public Library of Science One*. 2011;6(8):e23543.
79. Algotar AM, **Thompson PA**, Ranger-Moore J, Stratton MS, Hsu CH, Ahmann FR, Nagle RB, Stratton SP. Differences in characteristics of men with localised prostate cancer who demonstrate low, intermediate or high prostate-specific antigen velocity. *Internal Medicine Journal*. 2012;42(4):374–80.
80. Wertheim BC, Smith JW, Fang C, Alberts DS, Lance P, **Thompson PA**. Risk modification of colorectal adenoma by CYP7A1 polymorphisms and the role of bile acid metabolism in carcinogenesis. *Cancer Prevention Research*. 2012;5(2):197–204.
81. Butalla AC, Crane TE, Patil B, Wertheim BC, **Thompson P**, Thomson CA. Effects of a carrot juice intervention on plasma carotenoids, oxidative stress, and inflammation in overweight breast cancer survivors. *Nutrition and Cancer*. 2012;64(2):331–41.
82. Haile RW, John EM, Levine AJ, Cortessis VK, Unger JB, Gonzales M, Ziv E, **Thompson P**, Spruijt-Metz D, Tucker KL, Bernstein JL, Rohan TE, Ho GY, Bondy ML, Martínez ME, Cook L, Stern MC, Correa MC, Wright J, Schwartz SJ, Baezconde-Garbanati L, Blinder V, Miranda P, Hayes R, Friedman-Jiménez G, Monroe KR, Haiman CA, Henderson BE, Thomas DC, Boffetta P. A review of cancer in U.S. Hispanic populations. *Cancer Prevention Research*. 2012;5(2):150–63.
83. Garcia RZ, Carvajal SC, Wilkinson AV, **Thompson PA**, Nodora JN, Komenaka IK, Brewster A, Cruz GI, Wertheim BC, Bondy ML, Martínez ME. Factors that influence mammography use and breast cancer detection among Mexican-American and African-American women. *Cancer Causes & Control*. 2012;23(1):165–73.
84. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidid S, Meric-Bernstam F, Do KA, Hortobagyi GN, **Thompson PA**, Mills GB, Bondy ML, Blumenschein GR Jr. Frequency of MET and PIK3CA copy number elevation and correlation with outcome in early stage breast cancer. *Cancer*. 2012 Jun 26 [Epub ahead of print].
85. Liu Y, Melin BS, Rajaraman P, Wang Z, Linet M, Shete S, Amos CI, Lau CC, Scheurer ME, Tsavachidis S, Armstrong GN, Houlston RS, Hosking FJ, Claus EB, Barnholtz-Sloan J, Lai R, Il'yasova D, Schildkraut J, Sadetzki S, Johansen C, Bernstein JL, Olson SH, Jenkins RB, Lachance D, Vick NA, Wrensch M, Davis F, McCarthy BJ, Andersson U, **Thompson PA**,

- Chanock S, The Gliogene Consortium, Bondy ML. Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma. *Human Genetics*. 2012 Jun 12 [Epub ahead of print].
86. Martínez ME, Pond E, Wertheim BC, Nodora JN, Jacobs ET, Bondy M, Daneri-Navarro A, Meza-Montenegro MM, Gutierrez-Millan LE, Brewster A, Komenaka IK, Thompson P. Association Between Parity and Obesity in Mexican and Mexican-American Women: Findings from the Ella Binational Breast Cancer Study. *Journal of Immigrant and Minority Health*. 2012 May 23 [Epub ahead of print].
87. Vargas AJ, Wertheim BC, Gerner EW, Thomson CA, Rock CL, Thompson PA. Dietary polyamine intake and risk of colorectal adenomatous polyps, 2012 Jul;96(1):133-41.
88. Vargas AJ, **Thompson PA**. Diet and nutrient factors in colorectal cancer risk. *Nutr Clin Pract*. 2012 Oct;27(5):613-23. doi: 10.1177/0884533612454885. Epub 2012 Aug 14. Review
89. Vargas AJ, Wertheim BC, Gerner EW, Thomson CA, Rock CL, **Thompson PA**. Dietary polyamine intake and risk of colorectal adenomatous polyps. *Am J Clin Nutr*. 2012 Jul;96(1):133-41. doi: 10.3945/ajcn.111.030353. Epub 2012 May 30.
90. Garcia RZ, Carvajal SC, Wilkinson AV, **Thompson PA**, Nodora JN, Komenaka IK, Brewster A, Cruz GI, Wertheim BC, Bondy ML, Martínez ME. Factors that influence mammography use and breast cancer detection among Mexican-American and African-American women. *Cancer Causes Control*. 2012 Jan;23(1):165-73. doi: 10.1007/s10552-011-9865-x. Epub 2011 Nov 13.
91. Wertheim BC, Smith JW, Fang C, Alberts DS, Lance P, **Thompson PA**. Risk modification of colorectal adenoma by CYP7A1 polymorphisms and the role of bile acid metabolism in carcinogenesis. *Cancer Prev Res (Phila)*. 2012 Feb;5(2):197-204. doi: 10.1158/1940-6207.CAPR-11-0320. Epub 2011 Nov 4. PMID:
92. Abalos AT, Harris RB, Nyitray AG, Mitchell A, **Thompson PA**, Giuliano AR, Garcia F. Human papillomavirus type distribution among heterosexual couples. *J Low Genit Tract Dis*. 2012 Jan;16(1):10-5. doi: 10.1097/LGT.0b013e31822a8404
93. Martínez ME, **Thompson P**, Messer K, Ashbeck EL, Lieberman DA, Baron JA, Ahnen DJ, Robertson DJ, Jacobs ET, Greenberg ER, Cross AJ, Atkin W. One-year risk for advanced colorectal neoplasia: U.S. versus U.K. risk-stratification guidelines. *Ann Intern Med*. 2012 Dec 18;157(12):856-64. doi: 10.7326/0003-4819-157-12-201212180-00005.
94. **Thompson P**, Roe DJ, Fales L, Buckmeier J, Wang F, Hamilton SR, Bhattacharyya A, Green S, Hsu CH, Chow HH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Martinez ME, Jacobs E, Ashbeck EL, Alberts DS, Lance P. Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention. *Cancer Prev Res (Phila)*. 2012 Dec;5(12):1381-93. doi: 10.1158/1940-6207.CAPR-12-0204. Epub 2012 Oct 11.
95. Butalla AC, Crane TE, Patil B, Wertheim BC, **Thompson P**, Thomson CA. Effects of a carrot juice intervention on plasma carotenoids, oxidative stress, and inflammation in overweight breast cancer survivors. *Nutr Cancer*. 2012;64(2):331-41. doi: 10.1080/01635581.2012.650779. Epub 2012 Jan 31.
96. Vargas AJ, Wertheim BC, Gerner EW, Thomson CA, Rock CL, **Thompson PA**. Dietary polyamine intake and risk of colorectal adenomatous polyps. *Am J Clin Nutr*. 2012 Jul;96(1):133-41. doi: 10.3945/ajcn.111.030353. Epub 2012 May 30.
97. Thomson CA, **Thompson PA**., Fruit and vegetable intake and breast cancer risk: a case for subtype-specific risk? *J Natl Cancer Inst*. 2013 Feb 6;105(3):164-5. doi: 10.1093/jnci/djs640. Epub 2013 Jan 24. No abstract available.

98. Stendell-Hollis NR, **Thompson PA**, West JL, Wertheim BC, Thomson CA. A comparison of Mediterranean-style and MyPyramid diets on weight loss and inflammatory biomarkers in postpartum breastfeeding women. *J Womens Health (Larchmt)*. 2013 Jan;22(1):48-57. doi: 10.1089/jwh.2012.3707. Epub 2012 Dec 31.
99. Pande M, **Thompson PA**, Do KA, Sahin AA, Amos CI, Frazier ML, Bondy ML, Brewster AM. Genetic variants in the vitamin D pathway and breast cancer disease-free survival. *Carcinogenesis*. 2013 Mar;34(3):587-94. doi: 10.1093/carcin/bgs369. Epub 2012 Nov 24.
100. Cruz GI, Martínez ME, Natarajan L, Wertheim BC, Gago-Dominguez M, Bondy M, Daneri-Navarro A, Meza-Montenegro MM, Gutierrez-Millan LE, Brewster A, Schedin P, Komenaka IK, Castela JE, Carracedo A, Redondo CM, **Thompson PA**. Hypothesized role of pregnancy hormones on HER2+ breast tumor development. *Breast Cancer Res Treat*. 2013 Jan;137(1):237-46. doi: 10.1007/s10549-012-2313-0. Epub 2012 Nov 8.
101. Algotar AM, Stratton MS, Ahmann FR, Ranger-Moore J, Nagle RB, **Thompson PA**, Slate E, Hsu CH, Dalkin BL, Sindhvani P, Holmes MA, Tuckey JA, Graham DL, Parnes HL, Clark LC, Stratton SP. Phase 3 clinical trial investigating the effect of selenium supplementation in men at high-risk for prostate cancer. *Prostate*. 2013 Feb 15;73(3):328-35. doi: 10.1002/pros.22573. Epub 2012 Aug 10.
102. Liu Y, Melin BS, Rajaraman P, Wang Z, Linet M, Shete S, Amos CI, Lau CC, Scheurer ME, Tsavachidis S, Armstrong GN, Houlston RS, Hosking FJ, Claus EB, Barnholtz-Sloan J, Lai R, Il'yasova D, Schildkraut J, Sadetzki S, Johansen C, Bernstein JL, Olson SH, Jenkins RB, LaChance D, Vick NA, Wrensch M, Davis F, McCarthy BJ, Andersson U, **Thompson PA**, Chanock S; Gliogene Consortium, Bondy ML. Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma. *Cancer*. 2013 Jan 1;119(1):7-15. doi: 10.1002/cncr.27608. Epub 2012 Jun 26.
103. Bayraktar S, Thompson PA, Yoo SY, Do KA, Sahin AA, Arun BK, Bondy ML, Brewster AM. The Relationship Between Eight GWAS-Identified Single-Nucleotide Polymorphisms and Primary Breast Cancer Outcomes. *Oncologist*. 2013 May 1. [Epub ahead of print]

Electronic publication (peer-reviewed)

Swart R, Downey L, Lang J, **Thompson P**, Livingston RB, Stopeck AT. *Breast Cancer. eMedicine Oncology*. Online at <http://emedicine.medscape.com/article/283561-overview>.

Work in progress

1. Bartley AN, Parikh N, Hsu C-H, Roe D, Buckmeier JA, Gallick G, Lance P, **Thompson PA**, Hamilton SR. Colorectal adenoma stem-like cell populations and occurrence of metachronous colorectal neoplasia in high-risk patients. Under review, *Modern Pathology* (Thompson and Hamilton are co-senior authors).
2. Liu Y, Zhou R, Tsavachidis S, Brewster AM, Murray JL, Do K-A, Sahin A, Hortobagyi GN, Taube JH, Mani SA, Batts LM, Mills GB, Kamrudin S, Bondy ML, **Thompson PA**. Genome-wide molecular inversion probe array profiling reveals DNA copy number imbalances associated with breast cancer bone and non-bone metastasis. In revision, *Clinical Cancer Research*.
3. Cruz GI, Natarajan L, Wertheim BC, Gago-Dominguez M, Bondy ML, Daneri-Navarro A, Meza-Montenegro MM, Gutierrez-Millan LE, Brewster A, Schedin P, Komenaka IK, Castela JE, Carracedo A, Marey CR, Thompson PA, Martínez ME. Hypothesized role of pregnancy

hormones on HER2+ breast tumor development. Submitted, *Breast Cancer Research and Treatment* (Thompson and Martínez are co-senior authors).

4. Martínez EM, **Thompson PA**, Ashbeck EL, Lieberman DA, Baron JA, Ahnen DJ, Robertson DJ, Jacobs ET, Greenburg ER, Cross AJ, Atkin W. Risk of advanced neoplasia one-year post-polypectomy according to the U.S. and U.K. surveillance guidelines: a prospective analysis of pooled data. In revision, *Annals of Medicine*.
5. **PA Thompson**, DJ Roe, L Fales, J Buckmeier, F Wang, SR Hamilton, A Bhattacharyya, Green, CH Hsu, H-H Chow, DJ Ahnen, CR Boland, R Heigh, DE Fay, ME Martínez, EJ, EL Ashbeck, DS Alberts, P Lance. Design and baseline characteristics of study participants in a phase III randomized trial of celecoxib and selenium for the prevention of colorectal adenomas. In review, *Cancer Prevention Research*.
6. **Thompson PA**, Stopeck A. Breast Cancer Prevention. In Alberts DS, Hess LM (Eds.), *Fundamentals of Cancer Prevention, 3rd Edition* (pp. XX-XX). Berlin: Springer-Verlag. [Due Dec 2012.]
7. **Thompson PA**, Lance P. Colon and Rectal Cancer Prevention. In Alberts DS, Hess LM (Eds.), *Fundamentals of Cancer Prevention, 3rd Edition* (pp. XX-XX). Berlin: Springer-Verlag. [Due Dec 2012.]
8. **Thompson PA**, Roe DJ, Fales L, Buckmeier JA, Wang F, Hamilton SR, Bhattacharyya A, Green SB, Hsu CH, Chow H-H, Ahnen DJ, Boland CR, Heigh R, Fay DE, Martínez ME, E Jacobs, Ashbeck EL, Alberts DS, Lance P. Short-term celecoxib and prevention of colorectal adenoma. In preparation.
9. **Thompson PA**, Ljuslinder I, Tsavachidis S, Brewster A, Sahin A, Hedman H, Henriksson R, Melin BS, Bondy ML. *LRIG 1* copy number variations are associated with risk of relapse and intrinsic subtypes in stage I and II breast cancer. In preparation.

Symposia

1. "Catechol O-methyltransferase gene polymorphisms and risk of breast cancer." Invited lecturer at the Symposium on Estrogens as Initiators and Promoters in Breast and Prostate Cancer, Washington, DC, March, 1998.
2. "Cancer in hormonally-responsive tissue: role for chemical mutagenesis?" Invited speaker at the Environmental Mutagen Society 29th Annual Meeting, Anaheim, CA, March, 1998.
3. "Polymorphisms in carcinogen-metabolizing enzymes and their relevance to colorectal cancer: application of DNA MicroArray technology for genotyping in epidemiological studies." Invited lecturer at the Workshop on Interactions of Genetic and Environmental Factors, Maarsse, Netherlands, October, 1998.
4. "Advances in genotyping methodologies: promising new tools for the molecular epidemiologist." Invited lecturer at the Special Session of the Southwest Oncology Group Meeting, San Diego, CA, October, 1999.
5. "Advanced genotyping methods." Invited lecturer at the Roy Castle Workshop on Early Lung Cancer Detection, Liverpool, England, October, 1999.
6. "Molecular epidemiology – an untapped resource." Invited lecturer at the Roy Castle Workshop on Early Lung Cancer Detection, Liverpool, England, October, 1999.
7. "The use of microarray technology for the evaluation of host/tumor specific biomarker combinations in population based risk assessment and early detection of cancer." Invited lecturer at the Early Detection Research Network Scientific Workshop, Chicago, IL, September, 2000.

8. "The use of multi-analyte microarray technology for the evaluation of host/tumor protein biomarker combinations in cancer risk assessment and early detection." Invited poster presentation at the ACS Schilling Conference, Santa Cruz, CA, October, 2000.
9. "MTHFR genotype, folate and colorectal adenomatous polyps." Invited speaker at the NCI GI InterSPORE Pancreatic Meeting at The University of Texas MD Anderson Cancer Center, February, 2005.
10. "Early results: phase 1 study of sulindac for breast cancer prevention." Invited speaker at the NCI Division of Cancer Prevention Meeting on Stratified Cancer Prevention: Identifying Predictive Epithelial Markers for Breast Cancer Risk and Risk Reduction, Bethesda, MD, September, 2007.
11. "Candidate pathways, whole genome scans: reconciling results, looking into the future." Invited panel participant at the Candidate Pathways, Whole Genome Scans: Reconciling Results, Looking into the Future, Carefree, AZ, May, 2008.
12. "Trial results: phase 1 study of sulindac for breast cancer prevention." Invited speaker at the Seventh International Conference on Frontiers in Cancer Prevention Research, Washington, DC, November, 2008.
13. "Pooled high density sequencing for *BRCA* genes and risk management in Hispanic women." Invited Speaker at the Second American Association for Cancer Research Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Carefree, AZ, February, 2009.
14. "Next generation technologies and their use to address cancer related disparities." Workshop Chairperson at the Second American Association for Cancer Research Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Carefree, AZ, February, 2009.
15. "Trial results phase 1 study of sulindac for breast cancer prevention." Invited speaker at The Sixth International Symposium on the Intraductal Approach to Breast Cancer, Santa Monica, CA, February, 2009.
16. "Rectal polyamine and prostaglandin concentrations: risk and/or response biomarkers with difluoromethylornithine/sulindac treatment." Invited speaker at the NCI Translates: The 2009 NCI Translational Science Meeting (TSM 2) – GI/Pancreatic Cancer Breakout Sessions, Washington, DC, November, 2009.
17. Invited Speaker at the Third American Association for Cancer Research Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Miami, FL, September-October, 2010.
18. "Copy number imbalances and prediction models of early-stage breast cancer recurrence." Invited presentation at the Breast Cancer SPOREs Round Table, Washington, DC May 2010
19. "Race/ethnicity differences and copy number imbalances in outcomes of early stage breast cancer." The Fourth American Association for Cancer Research Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Washington, DC, September, 2011.
20. "Molecular biology of colorectal cancer." Colorectal Cancer Symposium, Tucson, AZ, November, 2011.
21. "Lessons learned from animal models of prevention and transdisciplinary studies." Invited speaker at the American Society of Preventive Oncology 36th Annual Meeting, Washington, DC, March, 2012.
22. "Replicating specific chromosomal imbalance determinants of early stage breast cancer recurrence identified using OncoScan™ FFPE Express in fresh frozen tumors across

platforms." Invited Speaker to the Affymetrix Cytogenetics Community at the American Cytogenetics Conference: Advances in Cytogenetics for Constitutional and Cancer Applications, San Antonio, TX, April, 2012

Seminars

1. "Biomarkers and prediction models for early stage breast cancer." Epidemiology Departmental Seminar, University of Arizona, Tucson, AZ, December, 2010.
2. "Novel findings of chromosomal imbalances in early stage breast cancer." Outcomes Institutional Grand Rounds, University of Texas MD Anderson Cancer Center, Houston, TX, February, 2011.
3. "KIR genes and HPV infection." Department of Medicine, Umea University Hospital, Umea, Sweden, February, 2011.
4. "Chromosomal imbalances in early stage breast cancer using OncoScan™ FFPE." Affymetrix Annual Corporate Retreat, San Francisco, CA, February, 2011.
5. "Colorectal polyp prevention trials: an experimental model of early epithelial neoplasia in man." Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX, March, 2011.
6. "Copy number predictors of breast cancer recurrence and biology of metastasis." Sarver Heart Seminar Series, University of Arizona, Tucson, AZ, April, 2011.
7. "Bile acids and colorectal cancer, what have we learned?" Nutritional Sciences Seminar Series, University of Arizona, Tucson, AZ, November, 2011.
8. "Bile acids and colorectal cancer, what have we learned?" Cancer Prevention and Control Seminar Series, University of Arizona Cancer Center, Tucson, AZ, November, 2011.
9. "Hypotheses: is colorectal cancer the result of loss of tumor surveillance, too much of one bacteria, or both?" Cancer Prevention and Control Seminar Series, University of Arizona Cancer Center, Tucson, AZ, February, 2012.

Grant Support

- | | |
|--|---|
| 1R01 CA151708-02 (Lance/Thompson, Joint PIs)
NIH/NCI
Selenium colorectal cancer chemoprevention trials | 08/01/11–06/30/14 1.80 cm
\$4,518,839 total entire project |
| The major goals of this program are to follow remaining selenium trial participants through study completion for all 1,800 participants in 2013, analyze data, and report findings. Another aim addresses the risk for type-2 diabetes incurred by the one-third of Americans using selenium-containing multivitamin and multi-mineral supplements. | |
| P30 CA023074-31 (Alberts, PI)
NIH/NCI
Arizona Cancer Center Support Grant | 07/01/04–06/30/14 1.20 cm
\$23,850 salary + IDC current yr. |
| Role: Program Leader, Cancer Prevention and Control
The major goal of this project is to provide organizational infrastructure for the promotion of interdisciplinary research and the collective use of resources. Funds for Dr. Lance support his roles as Program Leader and Senior Leader as Chief Cancer Control Officer at the Arizona Cancer Center. | |
| P50 CA95060 (Thompson, PI)
NIH/NCI
Specialized Program of Research Excellence (SPORE) in Gastrointestinal (GI) Cancer | 04/01/02–03/31/14 1.20 cm
\$11,494,409 entire project |

Role: PI, Co-Lead Project 1 and Career Development

The goal of this interdisciplinary SPORE is to prevent and cure GI cancers, through studies in prevention, genetics, and therapeutics.

1U01 CA153086 (Futscher, PI) 09/17/10–06/30/15 0.72 cm
NIH/NCI \$13,358 salary + IDC current yr.
Epigenetic features of pregnancy-associated breast cancer in Hispanic women
Role: Co-Investigator

The immediate objective of this research project is to compare the epidemiological and epigenetic profiles of breast cancer tumors diagnosed in the transient postpartum period of increased risk against those that are diagnosed outside this period.

1R01 ES019879 (Thomas, PI) 08/06/10–03/31/14 0.24 cm
NIH/NIEHS \$3636 salary + IDC current yr.
Title: Methods for pathway modeling with application to folate
Role: Site PI

The major goal of this study is to mathematically model the impact of genetic variation in the folate pathway on the biochemical processes of folate metabolism.

1R01 CA49417-02 (Thomson, PI) 09/20/10–07/31/15 1.32 cm
NIH/NCI \$24,963 salary + IDC current yr.
Evaluation of diindolylmethane supplementation to modulate tamoxifen efficacy in premenopausal breast cancer patients
Role: Co-Investigator

The major goal of this research is to test the efficacy and safety of diindolylmethane in women taking tamoxifen as adjuvant therapy for breast cancer.

N01-WH-2-2115 (Prentice, PI) 10/1/11–9/31/13 0.12 cm
NIH/NHLB \$2,359 salary + IDC current y
Women's Health Initiative (WHI) Extension Study Vanguard Clinical Center
Role: Co-Investigator

Title: Extension study of health outcomes in WHI study population

The major goal of the extension is to promote development of novel hypotheses among junior investigators for testing in the large population of postmenopausal women with long term follow-up for multiple diseases. I am currently mentoring two junior investigators on approved analyses within this cohort.

1R01 CA161534 (Thompson-Carino/Stopeck, Joint PIs) 07/01/12–04/30/16 2.40 cm
NIH/NCI \$1,701,129 total entire project

NSAID effects on clinical and imaging breast biomarkers

The goal of this project is to investigate the effect of sulindac combined with an aromatase inhibitor on breast density as measured by MRI.

R01CA157595 (Ignatenko, PI) 07/01/12-04/30/17 0.24 cm
NIH/NCI \$4,771 salary + IDC current yr.

Role of Kallikrein 6 expression and secretion in colon cancer

Role: Co-Investigator

The goal of the project is to investigate the role of kallikrein 6 secretion as a biomarker of colorectal cancer metastasis. My role is to provide technical expertise for the conduct of the biomarker analyses in blood and tissue.

1R01CA172511-01 (Thompson-Carino/Bondy/Brewster, MPIs) 01/01/13-12/31/17 1.80 cm
NIH/NCI \$2,959,875 total entire project

Risk Prediction for ER Negative Breast Cancer Recurrence

The goal of this study is to validate a risk prediction model for early stage ER negative breast cancer based on tumor genotype and to assess its performance in African American, Hispanic and Non-Hispanic Whites.

Pending

1P01CA181221-01 (Thompson-Carino/Smith, Joint PIs) 09/01/13-08/31/18 3.00 cm
NIH/NCI \$8,033,478 total entire project

The role of FXR in colorectal tumorigenesis

This program project consists of three highly related projects that collectively seek to demonstrate that the activation status of FXR in the colonic epithelium is a critical determinant of CRC and a strong target for intervention and risk reduction in humans.

1R01 CA172569-01 (Thompson-Carino, Gerner, LaFleur, MPI) 10/01/13–09/30/18 1.80 cm
NIH/NCI \$354,736 Direct year 1)

Targeting the polyamine and inflammatory pathways for colorectal cancer

Role: Co-PI

The goal of this project is to optimize strategies that reduce colorectal neoplasia by reducing polyamine exposures.

R01 (Thompson-Carino/Erdman,. Joint PIs) 07/01/13-06/30/18 1.20 cm
NIH/NCI \$395,178

Developing medical treatment for patients with FAP

SBIR (Jacob, PI) 04/01/13–03/31/15 0.60 cm
NIH \$39,019 (Direct)

Phase I: Prognostic and Predictive Markers for CPP-1x/sul

Role: Co-Investigator

Status: Score pending.

SBIR (Jacob, PI) 4/1/13–3/31/15 1.20 cm
NIH \$80,847 (Direct)

Phase II: Prognostic and Predictive Markers for CPP-1x/sul

Role: Co-Investigator

Status: Score Pending.

Industry (Thompson-Carino/Stopeck, Joint PIs) 02/01/13-01/31/15 1.20 cm
Amgen Pharmaceutical \$180,000 direct year 1

Phase II Study of Denosumab in patients at increased risk of breast cancer recurrence.

Completed

KG090934 (Thompson-Carino, PI) 02/1/09–05/31/13 0.60 cm
Susan G. Komen \$404,709 total entire project

Post-Baccalaureate Training Program to address breast cancer disparities in Mexican/Mexican-American women

The primary objective of this program is to provide a structured, tailored training program to empower students with the necessary skills to address and eliminate breast cancer health disparities in Hispanics and an outstanding opportunity to assess whether changing social and

cultural factors influence clinical, histological, and molecular patterns of breast cancer in women of Mexican descent.

5P01 CA041108-23 (Lance, PI) 8/1/05–7/31/11 3.60 cm
NIH/NCI

Colon Cancer Prevention Program Project

Role: Co-Investigator

Novel preventive strategies to prevent colon cancer and reduce the morbidity and mortality rate caused by colorectal cancer. Project III (Leader ME Martínez) gene-environment interaction studies related to folate and folate-metabolizing gene polymorphisms. Co-Leader Thompson directed large-scale haplotyping activity for genes involved in the regulation of IGF-1 and IGF signaling as risk factors in colon cancer.

5R01 AG027373-01 (Chen, PI) 09/01/07-06/30/12
NIH/NIA

Biomarkers and Genetic Factors Related to Sarcopenia in Older Women

Role: Co-Investigator

The major goals of this proposed work is to evaluate the role of genetic and biochemical determinants of sarcopenia in older women within a nested study of the Women's Health Initiative.

ODA-2578-GR-02 (Thompson, PI) 6/28/10-2/15/12
Oregon Department of Agriculture \$57,375 total
Role of fresh cherries in modulating biomarkers for cancer risk among males as risk for prostate cancer

5P30 CA023074-33S3 (Alberts, PI) 09/01/06-08/31/11
Arizona Cancer Center Support Grant Supplement
Comparative Study of Breast Cancer & their Risk Factors among Mexican Women in Mexico & the US.

Role: Dr. Thompson will establish the standard procedures for blood collection for genetic studies as well as conduct training. She will be responsible for the conduct of the admixture genetic analysis and will supervise a research assistant in her laboratory at the Arizona Cancer Center. She will serve as an expert resource for the team with regard to handling, storage and analysis of biologics for proposed genetic studies.

Goals: This is a supplement to the cancer center support grant. The project is a Comparative Study of Breast Cancers and their Risk Factors among Mexican Women in Mexico and the U.S.

Grant (Martínez, PI) 9/1/06–12/31/11 1.20 cm
Avon Foundation \$823,700 total

Comparative study of breast cancers and their risk factors among Mexican women in Mexico and the U.S.

Role: Co-investigator

The Arizona Cancer Center in collaboration with other institutions was awarded an NCI-Avon grant to assess whether changing social and cultural factors influence clinical, histological, and molecular patterns of breast cancer in women of Mexican descent.

5P50 CA116199 (Hortobagyi, PI) 10/01/05-09/30/11
NIH/NCI

MD Anderson SPORE in Breast Cancer

Role: Subcontract PI

Project 4: Tumor Genetic Characteristics and Breast Cancer Survival

Goal: Employ high density SNP arrays to assess whether changes in DNA copy number as single loci and/or co-occurring allele-specific imbalances differ by stage and correlate with known prognostic histopathologic and clinical variables and whether ethnicity affects the pattern of copy number aberrations, loci involved or degree of allelic imbalance in stage matched patients.

5P30 CA023074-30S3 (Martínez, PI) 9/1/06–12/31/09 1.20 cm
Avon Foundation Supplement to Cancer Center Support \$253,800

Grant

Comparative study of breast cancers and their risk factors among Mexican women in Mexico and the U.S.

Role: Co PI

The Arizona Cancer Center in collaboration with other institutions was awarded an NCI-Avon grant to assess whether changing social and cultural factors influence clinical, histological, and molecular patterns of breast cancer in women of Mexican descent.

List of Collaborators*

University of Arizona

David S. Alberts, MD

Scott Carvajal, PhD

Zhao Chen, PhD

H-H. Sherry Chow, PhD

Janine Einspahr, PhD

Eugene W. Gerner, PhD

Scott Going, Ph.D.

Stefano Guerra, PhD

Iman Hakim, MD, PhD, MPH

Chiu-Hsieh (Paul) Hsu, PhD

ChenChen Hu, PhD

Elizabeth Jacobs, PhD

Walter Klimecki, PhD

Peter Lance, MD

Bonnie Lafleur, PhD

Ana Maria Lopez, MD, MPH, FACP

Tim Lohman, PhD

Ray B. Nagle, MD, PhD

Denise J. Roe, DrPH

Joyce Schroeder, PhD

Alison T. Stopeck, MD

Steven Stratton, PhD

Cynthia A. Thomson, PhD

James A. Warneke, MD, FACS

Karen Weihs, MD

The University of Texas MD Anderson Cancer Center

Abenaa Brewster, MD

Stanley Hamilton, MD

Kim Ahn-Do, PhD

Ayse Sahin, MD

Savitri Krishnamurthy, MD

Henry Kuerer, MD

Ana Gonzalez-Angulo, MD

Gabriel Hortobagyi, MD

Bradley Broom, PhD

Mary Edgerton, MD

Other Institutions

Jason Zell, MD – University of California – Irvine, Irvine, CA

Frank Meyskens, MD – University of California - Irvine, Irvine, CA

Melissa Bondy, PhD – Baylor College of Medicine, Houston, TX

Michael Schuerer, PhD – Baylor College of Medicine, Houston, TX

María Elena Martínez, PhD – University of California - San Diego, San Diego, CA

Jesse Nodora, PhD – University of California - San Diego, San Diego, CA

Jim Petrosino, PhD – Baylor College of Medicine, Houston, TX

Joe Versolavic, MD – Baylor College of Medicine, Houston, TX

Joe Gray, PhD – McKnight Cancer Center, Portland, OR

Liana Tsikitis, MD – McKnight Cancer Center, Portland, OR

Sandhya Pruthi, MD – Mayo Cancer Center, Rochester, MN

Paul Limburg, MD – Mayo Cancer Center, Rochester, MN

Jeremy Nicholson, PhD – Imperial College, London, UK

Elaine Jacobsen, PhD – Imperial College, London, UK

Hector Kuen, PhD – Imperial College, London, UK

Wendy Atkin, PhD – Imperial College, London, UK

Bea Melin, MD – Medical University, Umea, Sweden

Ingrid Luislinder, MD – Medical University, Umea, Sweden

Manuela Gago, PhD – Complejo Hospitalario Universitario de Santiago, Galicia, Spain

Enrique Gutierrez-Millan, PhD – Universidad de Sonora, Hermosillo, MX

Adrian Daneri Navarro, PhD – Universidad de Guadalajara, Guadalajara, MX

Maria Mercedes Meza-Montenegro, PhD – Tecnológico de Sonora, Ciudad Obregón, MX

Ian Komenaka, MD – Maricopa Medical Center, Department of Surgery, Phoenix, AZ

Jeff Smith, PhD – Burnham Institute, San Diego, CA

Cheryl Rock, PhD – University of California – San Diego, San Diego, CA

Robert Haile, PhD – University of Southern California, Los Angeles, CA

John Baron, MD – University of North Carolina, Chapel Hill, NC
Duncan Thomas, PhD – University of Southern California, Los Angeles, CA
Larry Mandarino, PhD – Mayo Clinic, Scottsdale, AZ
Dennis Ahnen, MD – University of Colorado, Denver, CO
David Conti, PhD – University of Southern California, Los Angeles, CA
Christine McClaren, PhD – University of California - Irvine, CA
Jeff Weitzel, MD – The City of Hope Cancer Center, Los Angeles, CA

*Please Note: I have attempted to identify individuals with whom I am working currently or in the past 3-5 years. There may be individuals that I have failed to add. Any request for letters from reviewers should confirm that the person does not identify as a collaborator.

SIGNED STATEMENT

This is a true and accurate statement of my activities and accomplishments. I understand that misrepresentation in securing promotion and tenure may lead to dismissal or suspension under ABOR Policy 6-201 J.1.b.

Patricia A. Thompson-Carino, Ph.D.